CyberArk > 实例探究 > Pharmaceutical Leader AstraZeneca Collaborates Securely

Pharmaceutical Leader AstraZeneca Collaborates Securely

CyberArk Logo
公司规模
1,000+
地区
  • America
  • Europe
国家
  • United Kingdom
  • United States
产品
  • CyberArk Sensitive Information Management
  • CyberArk Vaulting Technology
技术栈
  • HTTPS
  • Public Key Infrastructure
  • RSA Security
  • Windows Domain Authentication
实施规模
  • Enterprise-wide Deployment
影响指标
  • Customer Satisfaction
  • Digital Expertise
  • Productivity Improvements
技术
  • 应用基础设施与中间件 - 数据交换与集成
  • 网络安全和隐私 - 身份认证管理
  • 网络安全和隐私 - 安全合规
适用行业
  • 医疗保健和医院
  • 药品
适用功能
  • 商业运营
  • 产品研发
用例
  • 远程协作
服务
  • 软件设计与工程服务
  • 系统集成
关于客户
AstraZeneca is a leading global pharmaceutical and healthcare services provider, headquartered in London, England. With an annual revenue of 21.4 billion Euros and over 84,000 employees, the company specializes in developing medicines for cancer, cardiovascular conditions, gastrointestinal disorders, the central nervous system, pain, and respiratory illnesses. AstraZeneca has a significant global presence, with 64,000 employees worldwide, including 12,000 in the United States. The company is heavily invested in research and development, spending $3.8 billion in 2004 alone, and employs 11,900 people dedicated to drug and treatment research. AstraZeneca's commitment to innovation and collaboration drives its need for secure and efficient information sharing solutions.
挑战
With $21.4 billion in annual sales, AstraZeneca is one of the top five pharmaceutical and health care services providers in the world. The pharmaceutical industry is highly competitive and regulated. In 2004, AstraZeneca invested $3.8 billion into new drug research and development, employing 11,900 people dedicated to this task. The company needed a secure and manageable way to collaborate internally and with external partners. Previously, AstraZeneca used an in-house secure collaborative application requiring a VPN client on each user’s system, which proved to be a high-management burden. Frequent help-desk calls and firewall adjustments were common issues. AstraZeneca needed a seamless, web-based solution with no setup overhead or firewall concerns.
解决方案
AstraZeneca chose CyberArk’s Sensitive Information Management solution after several internal pilots. The solution proved easy to deploy and maintain, requiring no code tweaks. CyberArk’s Vaulting Technology creates information 'safe havens' with layered security protection, including integrated firewall, authentication, access control, session and data encryption, content inspection, secure backup, and version control. End users need only a web browser to access the secure vaults, with information secured via HTTPS and specialized encryption. The solution supports various authentication methods, including public key infrastructure, RSA security, and Windows Domain authentication. Security managers can create specific access rights, limiting user and vault activity. AstraZeneca first deployed the solution within its drug development process, where it significantly sped up data and document exchange with business partners. The solution's version control mechanism prevents data corruption, proving extremely useful. AstraZeneca now uses the solution organization-wide, creating secure collaborative workgroups quickly and efficiently.
运营影响
  • CyberArk’s Sensitive Information Management solution enabled AstraZeneca to exchange data and documents more quickly with business partners, significantly speeding up the drug development process.
  • The solution's powerful version-control mechanism protects against deliberate and unintentional data corruption, ensuring data integrity.
  • The ease of deployment and maintenance of CyberArk’s solution reduced the high-management burden previously experienced with the in-house application.
  • The web-based solution eliminated the need for VPN clients and firewall adjustments, simplifying the user experience and reducing help-desk calls.
  • AstraZeneca now uses the solution organization-wide, creating secure collaborative workgroups quickly and efficiently, enhancing overall productivity and collaboration.
数量效益
  • AstraZeneca invested $3.8 billion into new drug research and development in 2004.
  • The company employs 11,900 people dedicated to drug and treatment research and development.
  • It is estimated that it costs pharmaceutical companies $1 million for each day a drug is under development.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

相关案例.

联系我们

欢迎与我们交流!
* Required
* Required
* Required
* Invalid email address
提交此表单,即表示您同意 IoT ONE 可以与您联系并分享洞察和营销信息。
不,谢谢,我不想收到来自 IoT ONE 的任何营销电子邮件。
提交

感谢您的信息!
我们会很快与你取得联系。